{"nctId":"NCT00978380","briefTitle":"Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725","startDateStruct":{"date":"2009-09-21","type":"ACTUAL"},"conditions":["Congenital Bleeding Disorder","Congenital FXIII Deficiency"],"count":63,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: catridecacog"]}],"interventions":[{"name":"catridecacog","otherNames":["recombinant factor XIII"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* For subjects who participated in F13CD-1725:\n* Previous participation (means up to and inclusive Visit 16, (End of Trial)) in F13CD-1725\n* For all other subjects:\n* Diagnosis of congenital FXIII A-subunit deficiency (confirmed by genotyping at screening visit or documented results from previously performed genotyping)\n* Body weight at least 20 kg\n\nExclusion Criteria:\n\n* Known neutralizing antibodies (inhibitors) towards FXIII\n* Any known congenital or acquired coagulation disorder other than congenital FXIII deficiency\n* Platelet count (thrombocytes) of less than 50 Ã— 109/L. For subjects who participated in F13CD-1725 platelet count from visit 15 in F13CD-1725 must be used for evaluation.\n* Females of childbearing potential who are pregnant, breastfeeding or are not using adequate contraceptive methods","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adverse Events (AEs)(Serious and Non-serious)","description":"An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Trial AEs (serious) included any event such as death, life-threatening experience, in-subject hospitalisation, significant disability/ congential anomaly experienced from the trial product.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"920","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"901","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody and Inhibitor Development","description":"All subjects who received rFXIII were monitored for anti-rFXIII antibodies and inhibitor development. Samples passed through 2 tiers of ELISA testing: an initial screen with a specific cut-off point (including \\~5% false positives) and a second confirmatory assay for samples yielding a result above the screening cut-off point. If samples were confirmed as antibody positive in the confirmation assay, an inhibitor assay was also carried out to detect functional inhibitors. Percentage of subjects with antibody and inhibitor development were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":59},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection","Contusion","Pain in extremity"]}}}